Blood test for p-tau217 may predict cognitive decline within 5 to 10 years, Mayo Clinic study finds

The test measures a protein linked to Alzheimer's disease, but the researchers say it is not ready for routine screening.

A new Mayo Clinic study published in JAMA Neurology suggests that a blood test detecting a protein linked to Alzheimer's disease could help forecast whether older adults will show cognitive decline within five to 10 years.

The researchers measured phosphorylated tau 217 (p-tau217) in 2,178 cognitively unimpaired adults between 60 and 90 years old. Participants came from the Mayo Clinic Study of Aging and the Alzheimer's Disease Neuroimaging Initiative, and they received blood biomarker tests, genetic tests and several cognitive assessments.

Age, gender and carriage of the APOE ε4 variant, which is associated with Alzheimer's risk, were also considered in the analysis. After p-tau217 was taken into account, APOE ε4 showed a modest link with risk, while older age was linked to greater risk. For example, at the same elevated p-tau217 level, a 65-year-old had an estimated five-year risk of mild cognitive impairment of 6%, compared with 37% for an 85-year-old.

Clifford Jack Jr., a Mayo Clinic neuroradiologist and the senior author, said the test shows from a blood sample whether someone has the pathology in the brain. Detecting p-tau217 in blood may be less invasive and potentially more scalable than PET scans that measure amyloid burden.

The risk estimates were developed in a population from southeast Minnesota, and Jack said the findings need to be replicated elsewhere. The test is not yet ready for routine screening of people without cognitive symptoms. Jack said there is no approved treatment for asymptomatic people who have the disease in the brain.

Key facts

  • The study included 2,178 cognitively unimpaired adults aged 60 to 90.
  • The test may predict cognitive decline risk within five to 10 years.
  • At the same p-tau217 level, a 65-year-old had a 6% estimated five-year risk of mild cognitive impairment, versus 37% for an 85-year-old.

Three perspectives

Neutral

A Mayo Clinic study published in JAMA Neurology found that a blood test measuring p-tau217 may help predict cognitive decline within five to 10 years.

Positive

If preventive treatments become available, this kind of information could help patients and clinicians have more informed conversations about treatment.

Negative

The risk prediction model is not yet ready for routine screening of people without cognitive symptoms.

Your week in news, every Wednesday

The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.

Choose your news coverage

Please choose and confirm your coverage.

Beer and spirits linked to higher risk of acute kidney injury
Next storyBeer and spirits linked to higher risk of acute kidney injury

All sections

Edition